NCT05194293View on ClinicalTrials.gov

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 5, 2025

Study Completion Date

December 5, 2028

Conditions
Stage IB Hepatocellular Carcinoma AJCC v8Stage II Hepatocellular Carcinoma AJCC v8Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8
Interventions
BIOLOGICAL

Durvalumab

Given IV

DRUG

Regorafenib

Given PO

Trial Locations (3)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

35233

University of Alabama at Birmingham Cancer Center, Birmingham

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER